TQ Therapeutics

🗓 Founded 2023👥 8 employees💰 Last funded Jan 2024
Biotechnology Research🌐 tqtherapeutics.com
Website LinkedIn
TQx WILL SHIFT PARADIGMS IN CELL & GENE THERAPY. The TQx platform will transform the traditional way of producing cellular therapies, which is often slow, expensive, and hard to scale, into a very fast and highly automated process right at the patients side. This method uses extra-corporeal gene therapy but keeps the benefits of autologous cell therapy, where patients receive treatments made from their own cells. Our TQx method makes it easier to create genetically modified immune cells (like CAR-T cells) and deliver cell therapy directly to the patient. This avoids the complicated and costly steps of centralized production. As a result, this approach unlocks the full potential of autologous cell therapies for treating conditions that were previously difficult to address, including rare autoimmune diseases and cancers.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2023
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in TQ Therapeutics?
TQ Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did TQ Therapeutics last raise funding?
The most recent investment in TQ Therapeutics recorded on gritt.io was in January 2024.
When was TQ Therapeutics founded?
TQ Therapeutics was founded in 2023.
What industry is TQ Therapeutics in?
TQ Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.